Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia - News-Medical.Net

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for ...

Abilify Does Well in Depot Version - MedPage Today

Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston and Dorothy Caputo, MA, BSN, RN, Nurse Planner PHILADELPHIA -- A depot formulation of aripiprazole (Abilify) is on track to join the ranks ...

Long-term Injectable Drug Effective for Schizophrenia - Medscape News

May 11, 2012 (Philadelphia, Pennsylvania) — Intramuscular depot aripiprazole is a safe and tolerable option for long-term maintenance treatment of schizophrenia, according to several presentations from a new large trial presented here at the American ...

Phase 3 Study of Aripiprazole Intramuscular Depot for the Maintenance Treatment of Schizophrenia - Monthly Prescribing Reference

Otsuka and Lundbeck announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia. This Phase 3 ...

Otsuka Wins Appeal Ruling Upholding Abilify Drug Patent - Businessweek

Abilify, also known by its active ingredient aripiprazole, was first approved by U.S. regulators in 2002. New York-based Bristol-Myers reported its share of Abilify sales was $2.76 billion last year, or 13 percent of the company’s revenue.

Schizophrenia drug trial data a boost for Lundbeck - Reuters

The trial, with a once-monthly dose of a compound called aripiprazole intramuscular (IM) depot formulation, hit its primary target - to prolong the time to relapse in the maintenance treatment of schizophrenia, Lundbeck said in a statement.

Drugs in the Pipeline - Monthly Prescribing Reference

Otsuka and Lundbeck announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia. Download the ...

Drugs that can make you gain weight - FOX News

The diabetes drug metformin may help keep weight off, as can switching to weight-neutral antipsychotics like Geodon (ziprasidone) and Abilify (aripiprazole). Oral corticosteroids, such as Deltasone, are more potent than inhaled forms and carry a ...

Increased risk of death associated with off-label use of antipsychotic drugs to treat psicosis in older people with dementia - Xagena Medical News

The medications involved in this action are: Compazine ( Prochlorperazine ), Abilify ( Aripiprazole ), Haldol ( Haloperidol ), Clozaril ( Clozapine ), Loxitane ( Loxapine ), FazaClo ( Clozapine ), Mellaril ( Thioridazine ), Geodon ( Ziprasidone ), Moban ...

The Federal Circuit Decision Affirming the Validity of the Asserted Claims of Otsuka’s Patent to Abilify - Phramalive.com

holding that the asserted claims of U.S. Patent No. 5,006,528 covering aripiprazole, the active ingredient in ABILIFY®, are valid, thus maintaining patent and regulatory protection for ABILIFY® in the United States until at least April 20, 2015.